[Morning session on the second day of the 2026 National Talks: Negotiations on some oncology drugs begin Representatives from Chinese and foreign companies such as Heyuan Biotech, Astellas, Hengrui Pharmaceuticals, etc. attended the event] On September 6, reporters learned from the on-site negotiations on the 2026 National Medical Insurance Catalog and the Price Negotiation on the Commercially Insured Innovative Drug Catalog that the second day of the 2026 National Talks was held on August 8 Starting around 12:00 p.m., representatives from nearly 20 domestic and foreign pharmaceutical companies, including Heyuan Biologics, Yuanda Pharmaceuticals, Hengrui Pharmaceuticals, Qilu Pharmaceuticals, Eli Lilly, Chia Tai Tianqing, a subsidiary of China National Biopharmaceuticals, CSPC Pharmaceutical Group, Sanofi, Innovent Biologics, and Novartis, entered the venue one after another to start negotiations. Among them, Heyuan Biotech's CAR-T drug Nachiolense Injection entered the Commercial Insurance Innovative Drug Catalogue last year. This year, it applied to enter the Basic Medical Insurance Catalog and passed the preliminary review. It also applied for adjustment of indications in the Commercial Insurance Catalog. It is expected that the types of drugs negotiated in the morning will include tumor treatment drugs. (Reporters Lu Afeng and Yu Miao)